The Experts below are selected from a list of 894 Experts worldwide ranked by ideXlab platform
Dawei Wang - One of the best experts on this subject based on the ideXlab platform.
-
oral administration of Lactobacillus Casei Shirota improves recovery of hand functions after distal radius fracture among elder patients a placebo controlled double blind and randomized trial
Journal of Orthopaedic Surgery and Research, 2019Co-Authors: Chunhua Zhang, Sujuan Xue, Yong Wang, Limei Hua, Chunhua Guo, Dawei Wang, Min LeiAbstract:To evaluate the effect of oral Lactobacillus Casei Shirota (LcS) administration on recovery of hand functions in senior patients diagnosed with an acute distal radius fracture. This clinical trial is double-blind and placebo-controlled, in which 293 senior patients with distal radius fracture were initially enrolled. After exclusion, 264 eligible patients were randomly assigned to receive oral placebo or LcS daily for a period of 3 months after the fracture. Treatment outcomes were Michigan Hand Questionnaire (MHQ) score, radial deviation and inclination, and ulnar deviation and variance, all of which were monitored and measured every month. Throughout the length of this study, MHQ score, radial deviation and inclination, and ulnar deviation and variance of patients on oral LcS displayed a significantly faster improvement in comparison to those receiving placebo, over the 3-month intervention period. Oral administration of LcS dramatically accelerated hand function recovery in senior patients with distal radius fracture.
-
oral administration of probiotic Lactobacillus Casei Shirota decreases pneumonia and increases pulmonary functions after single rib fracture a randomized double blind placebo controlled clinical trial
Journal of Food Science, 2018Co-Authors: Chunhua Guo, Chunhua Zhang, Sujuan Xue, Yong Wang, Limei Hua, Min Lei, Dawei WangAbstract:Considerate proportion of elderly patients with a rib fracture is susceptible to pulmonary complications, especially pneumonia. We aimed to assess the effect of oral administration of the probiotic Lactobacillus Casei Shirota(LcS) on pneumonia and pulmonary functions among elderly patients with single rib fracture. The current study including 204 eligible elderly patients with a single rib fracture was conducted. Patients were randomly assigned to receive oral administration of skimmed milk containing either a commercial probiotic LcS or placebo daily for 1 mo after the fracture, followed by pneumonia assessments, pulmonary function testing including forced expiratory volume (FEV), negative inspiratory pressure (NIP), and forced vital capacity (FVC), as well as evaluation of potential adverse effects including myocardial infarction, acute kidney injury, nonunion of fractured bone, or stroke. After 1 mo consumption, patients in the LcS group exhibited decreased pneumonia and increased recovery of pulmonary functions, in terms of FEV, FVC, and NIP, compared to the placebo group. No difference was observed in incidence of adverse events between the 2 groups. In patients with a single rib fracture, oral administration of the probiotic LcS was associated with a lower incidence of pneumonia and increased pulmonary functions without causing severe adverse effects. To conclude, after 1‐mo LcS consumption, in patients with a single rib fracture, oral administration of the probiotic LcS was associated with a lower incidence of pneumonia and increased pulmonary functions without causing severe adverse effects.
-
oral administration of probiotic Lactobacillus Casei Shirota relieves pain after single rib fracture a randomized double blind placebo controlled clinical trial
Asia Pacific Journal of Clinical Nutrition, 2018Co-Authors: Min Lei, Chunhua Zhang, Sujuan Xue, Yong Wang, Limei Hua, Chunhua Guo, Dawei WangAbstract:Background and Objectives: Probiotic treatment has proven to increase the density of bone mass, prevent against bone loss, and improve bone formation. We aimed to assess the effect of oral administration of the probiotic Lactobacillus Casei Shirota (LcS) on pain relief in patients with single rib fracture. Methods and Study Design: A total of 283 eligible patients who had a single rib fracture were enrolled and randomly assigned to receive skimmed milk containing either a commercial probiotic LcS or placebo every day through oral administration for 1 month after the fracture. The pain relief effect was assessed during activities that elicited pain; meanwhile, sleep quality and sustained maximal inspiration (SMI) lung volumes were monitored. Results: Patients in the LcS group had more effective pain relief than those in the placebo group during deep breathing, coughing and turning over the body. Between the two groups of patients, increase in SMI lung volume was larger in LcS group patients than that of patients in the placebo group. Sleep quality did not show significant improvements after 1 month LcS treatment. Conclusions: In patients with a single rib fracture, oral administration of the probiotic LcS could exhibit alleviating effects on pain intensity.
-
the effect of probiotic Lactobacillus Casei Shirota on knee osteoarthritis a randomised double blind placebo controlled clinical trial
Beneficial Microbes, 2017Co-Authors: Min Lei, Chunhua Zhang, Chunhua Guo, Dawei Wang, L M HuaAbstract:Knee osteoarthritis (OA) treatment is challenging due to inefficacy and adverse effects of current medications. Probiotic treatment has been shown to promote bone metabolism, reduce pain and inflammatory responses of age-related musculoskeletal disorders, including OA. We aimed to investigate the effect of probiotic Lactobacillus Casei Shirota (LcS) on patients with knee OA. 537 patients with knee OA were enrolled in this double-blind, placebo-controlled trial, who were randomised to receive skimmed milk containing either LcS or placebo daily for 6 months. Primary outcome was defined as changes in WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) and VAS (visual analog scale) scores. Secondary outcome was defined as changes in serum levels of high sensitivity C-reactive protein (hs-CRP). After 6 months of treatment, both WOMAC and VAS scores were significantly improved in the LcS groups of patients compared to the placebo group. Serum levels of hs-CRP were also significantly lower in ...
Min Lei - One of the best experts on this subject based on the ideXlab platform.
-
oral administration of Lactobacillus Casei Shirota improves recovery of hand functions after distal radius fracture among elder patients a placebo controlled double blind and randomized trial
Journal of Orthopaedic Surgery and Research, 2019Co-Authors: Chunhua Zhang, Sujuan Xue, Yong Wang, Limei Hua, Chunhua Guo, Dawei Wang, Min LeiAbstract:To evaluate the effect of oral Lactobacillus Casei Shirota (LcS) administration on recovery of hand functions in senior patients diagnosed with an acute distal radius fracture. This clinical trial is double-blind and placebo-controlled, in which 293 senior patients with distal radius fracture were initially enrolled. After exclusion, 264 eligible patients were randomly assigned to receive oral placebo or LcS daily for a period of 3 months after the fracture. Treatment outcomes were Michigan Hand Questionnaire (MHQ) score, radial deviation and inclination, and ulnar deviation and variance, all of which were monitored and measured every month. Throughout the length of this study, MHQ score, radial deviation and inclination, and ulnar deviation and variance of patients on oral LcS displayed a significantly faster improvement in comparison to those receiving placebo, over the 3-month intervention period. Oral administration of LcS dramatically accelerated hand function recovery in senior patients with distal radius fracture.
-
oral administration of probiotic Lactobacillus Casei Shirota decreases pneumonia and increases pulmonary functions after single rib fracture a randomized double blind placebo controlled clinical trial
Journal of Food Science, 2018Co-Authors: Chunhua Guo, Chunhua Zhang, Sujuan Xue, Yong Wang, Limei Hua, Min Lei, Dawei WangAbstract:Considerate proportion of elderly patients with a rib fracture is susceptible to pulmonary complications, especially pneumonia. We aimed to assess the effect of oral administration of the probiotic Lactobacillus Casei Shirota(LcS) on pneumonia and pulmonary functions among elderly patients with single rib fracture. The current study including 204 eligible elderly patients with a single rib fracture was conducted. Patients were randomly assigned to receive oral administration of skimmed milk containing either a commercial probiotic LcS or placebo daily for 1 mo after the fracture, followed by pneumonia assessments, pulmonary function testing including forced expiratory volume (FEV), negative inspiratory pressure (NIP), and forced vital capacity (FVC), as well as evaluation of potential adverse effects including myocardial infarction, acute kidney injury, nonunion of fractured bone, or stroke. After 1 mo consumption, patients in the LcS group exhibited decreased pneumonia and increased recovery of pulmonary functions, in terms of FEV, FVC, and NIP, compared to the placebo group. No difference was observed in incidence of adverse events between the 2 groups. In patients with a single rib fracture, oral administration of the probiotic LcS was associated with a lower incidence of pneumonia and increased pulmonary functions without causing severe adverse effects. To conclude, after 1‐mo LcS consumption, in patients with a single rib fracture, oral administration of the probiotic LcS was associated with a lower incidence of pneumonia and increased pulmonary functions without causing severe adverse effects.
-
oral administration of probiotic Lactobacillus Casei Shirota relieves pain after single rib fracture a randomized double blind placebo controlled clinical trial
Asia Pacific Journal of Clinical Nutrition, 2018Co-Authors: Min Lei, Chunhua Zhang, Sujuan Xue, Yong Wang, Limei Hua, Chunhua Guo, Dawei WangAbstract:Background and Objectives: Probiotic treatment has proven to increase the density of bone mass, prevent against bone loss, and improve bone formation. We aimed to assess the effect of oral administration of the probiotic Lactobacillus Casei Shirota (LcS) on pain relief in patients with single rib fracture. Methods and Study Design: A total of 283 eligible patients who had a single rib fracture were enrolled and randomly assigned to receive skimmed milk containing either a commercial probiotic LcS or placebo every day through oral administration for 1 month after the fracture. The pain relief effect was assessed during activities that elicited pain; meanwhile, sleep quality and sustained maximal inspiration (SMI) lung volumes were monitored. Results: Patients in the LcS group had more effective pain relief than those in the placebo group during deep breathing, coughing and turning over the body. Between the two groups of patients, increase in SMI lung volume was larger in LcS group patients than that of patients in the placebo group. Sleep quality did not show significant improvements after 1 month LcS treatment. Conclusions: In patients with a single rib fracture, oral administration of the probiotic LcS could exhibit alleviating effects on pain intensity.
-
the effect of probiotic Lactobacillus Casei Shirota on knee osteoarthritis a randomised double blind placebo controlled clinical trial
Beneficial Microbes, 2017Co-Authors: Min Lei, Chunhua Zhang, Chunhua Guo, Dawei Wang, L M HuaAbstract:Knee osteoarthritis (OA) treatment is challenging due to inefficacy and adverse effects of current medications. Probiotic treatment has been shown to promote bone metabolism, reduce pain and inflammatory responses of age-related musculoskeletal disorders, including OA. We aimed to investigate the effect of probiotic Lactobacillus Casei Shirota (LcS) on patients with knee OA. 537 patients with knee OA were enrolled in this double-blind, placebo-controlled trial, who were randomised to receive skimmed milk containing either LcS or placebo daily for 6 months. Primary outcome was defined as changes in WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) and VAS (visual analog scale) scores. Secondary outcome was defined as changes in serum levels of high sensitivity C-reactive protein (hs-CRP). After 6 months of treatment, both WOMAC and VAS scores were significantly improved in the LcS groups of patients compared to the placebo group. Serum levels of hs-CRP were also significantly lower in ...
Chunhua Guo - One of the best experts on this subject based on the ideXlab platform.
-
oral administration of Lactobacillus Casei Shirota improves recovery of hand functions after distal radius fracture among elder patients a placebo controlled double blind and randomized trial
Journal of Orthopaedic Surgery and Research, 2019Co-Authors: Chunhua Zhang, Sujuan Xue, Yong Wang, Limei Hua, Chunhua Guo, Dawei Wang, Min LeiAbstract:To evaluate the effect of oral Lactobacillus Casei Shirota (LcS) administration on recovery of hand functions in senior patients diagnosed with an acute distal radius fracture. This clinical trial is double-blind and placebo-controlled, in which 293 senior patients with distal radius fracture were initially enrolled. After exclusion, 264 eligible patients were randomly assigned to receive oral placebo or LcS daily for a period of 3 months after the fracture. Treatment outcomes were Michigan Hand Questionnaire (MHQ) score, radial deviation and inclination, and ulnar deviation and variance, all of which were monitored and measured every month. Throughout the length of this study, MHQ score, radial deviation and inclination, and ulnar deviation and variance of patients on oral LcS displayed a significantly faster improvement in comparison to those receiving placebo, over the 3-month intervention period. Oral administration of LcS dramatically accelerated hand function recovery in senior patients with distal radius fracture.
-
oral administration of probiotic Lactobacillus Casei Shirota decreases pneumonia and increases pulmonary functions after single rib fracture a randomized double blind placebo controlled clinical trial
Journal of Food Science, 2018Co-Authors: Chunhua Guo, Chunhua Zhang, Sujuan Xue, Yong Wang, Limei Hua, Min Lei, Dawei WangAbstract:Considerate proportion of elderly patients with a rib fracture is susceptible to pulmonary complications, especially pneumonia. We aimed to assess the effect of oral administration of the probiotic Lactobacillus Casei Shirota(LcS) on pneumonia and pulmonary functions among elderly patients with single rib fracture. The current study including 204 eligible elderly patients with a single rib fracture was conducted. Patients were randomly assigned to receive oral administration of skimmed milk containing either a commercial probiotic LcS or placebo daily for 1 mo after the fracture, followed by pneumonia assessments, pulmonary function testing including forced expiratory volume (FEV), negative inspiratory pressure (NIP), and forced vital capacity (FVC), as well as evaluation of potential adverse effects including myocardial infarction, acute kidney injury, nonunion of fractured bone, or stroke. After 1 mo consumption, patients in the LcS group exhibited decreased pneumonia and increased recovery of pulmonary functions, in terms of FEV, FVC, and NIP, compared to the placebo group. No difference was observed in incidence of adverse events between the 2 groups. In patients with a single rib fracture, oral administration of the probiotic LcS was associated with a lower incidence of pneumonia and increased pulmonary functions without causing severe adverse effects. To conclude, after 1‐mo LcS consumption, in patients with a single rib fracture, oral administration of the probiotic LcS was associated with a lower incidence of pneumonia and increased pulmonary functions without causing severe adverse effects.
-
oral administration of probiotic Lactobacillus Casei Shirota relieves pain after single rib fracture a randomized double blind placebo controlled clinical trial
Asia Pacific Journal of Clinical Nutrition, 2018Co-Authors: Min Lei, Chunhua Zhang, Sujuan Xue, Yong Wang, Limei Hua, Chunhua Guo, Dawei WangAbstract:Background and Objectives: Probiotic treatment has proven to increase the density of bone mass, prevent against bone loss, and improve bone formation. We aimed to assess the effect of oral administration of the probiotic Lactobacillus Casei Shirota (LcS) on pain relief in patients with single rib fracture. Methods and Study Design: A total of 283 eligible patients who had a single rib fracture were enrolled and randomly assigned to receive skimmed milk containing either a commercial probiotic LcS or placebo every day through oral administration for 1 month after the fracture. The pain relief effect was assessed during activities that elicited pain; meanwhile, sleep quality and sustained maximal inspiration (SMI) lung volumes were monitored. Results: Patients in the LcS group had more effective pain relief than those in the placebo group during deep breathing, coughing and turning over the body. Between the two groups of patients, increase in SMI lung volume was larger in LcS group patients than that of patients in the placebo group. Sleep quality did not show significant improvements after 1 month LcS treatment. Conclusions: In patients with a single rib fracture, oral administration of the probiotic LcS could exhibit alleviating effects on pain intensity.
-
the effect of probiotic Lactobacillus Casei Shirota on knee osteoarthritis a randomised double blind placebo controlled clinical trial
Beneficial Microbes, 2017Co-Authors: Min Lei, Chunhua Zhang, Chunhua Guo, Dawei Wang, L M HuaAbstract:Knee osteoarthritis (OA) treatment is challenging due to inefficacy and adverse effects of current medications. Probiotic treatment has been shown to promote bone metabolism, reduce pain and inflammatory responses of age-related musculoskeletal disorders, including OA. We aimed to investigate the effect of probiotic Lactobacillus Casei Shirota (LcS) on patients with knee OA. 537 patients with knee OA were enrolled in this double-blind, placebo-controlled trial, who were randomised to receive skimmed milk containing either LcS or placebo daily for 6 months. Primary outcome was defined as changes in WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) and VAS (visual analog scale) scores. Secondary outcome was defined as changes in serum levels of high sensitivity C-reactive protein (hs-CRP). After 6 months of treatment, both WOMAC and VAS scores were significantly improved in the LcS groups of patients compared to the placebo group. Serum levels of hs-CRP were also significantly lower in ...
Parveen Yaqoob - One of the best experts on this subject based on the ideXlab platform.
-
immunomodulatory effects of a probiotic drink containing Lactobacillus Casei Shirota in healthy older volunteers
European Journal of Nutrition, 2013Co-Authors: Honglin Dong, Ian Rowland, Linda V Thomas, Parveen YaqoobAbstract:There is growing evidence that probiotics confer health benefits to the host by modulating immune function, especially in older people, where immunosenescence is a feature even of healthy ageing. The aim of this study was to investigate the effect of a probiotic drink containing Lactobacillus Casei Shirota (LcS) on immune function in a healthy non-immunocompromised older population. Thirty healthy old volunteers were recruited into a randomized placebo-controlled, single-blind crossover study. The volunteers were supplemented with the probiotic drink containing 1.3 × 1010 CFU LcS or skimmed milk per day for 4 weeks, followed by 4 weeks of washout and were crossed over to the other treatment. Peripheral blood and saliva samples were collected at baseline and end of each treatment. Probiotic consumption was associated with a significant increase in natural killer (NK) cell activity relative to baseline and a significant decrease in the mean fluorescence intensity of CD25 expression in the resting T cells compared with placebo. Additionally, there was a trend towards an increased ratio of IL-10 to IL-12 relative to baseline after LcS intake. Consumption of a probiotic drink containing LcS improved NK cell activity and tended to produce a more anti-inflammatory cytokine profile in an older population.
-
evidence of immunomodulatory effects of a novel probiotic bifidobacterium longum bv infantis ccug 52486
Fems Immunology and Medical Microbiology, 2012Co-Authors: Jialu You, Parveen YaqoobAbstract:Bifidobacterium longum bv. infantis CCUG 52486 was originally isolated from healthy elderly subjects and demonstrated to have particular ecological fitness and anti-pathogenic effects. Bifidobacteria are commonly associated with immuno-modulatory properties, especially in older people, but this strain has not been investigated for effects on immune function. This study aimed to explore the immunomodulatory effects of this novel probiotic, compared with three commercial strains, B. longum SP 07/3, Lactobacillus rhamnosus GG (L.GG) and Lactobacillus Casei Shirota (LcS). Human peripheral blood mononuclear cells (PBMCs) were isolated from fasting blood of young or older volunteers and exposed to probiotic strains or Con A. NK activity and activation, and cytokine release was enhanced by all probiotics with strain specificities. The effect of B. infantis on NK activity was influenced by ageing. Except for L.GG, probiotics increased IFN-γ production to a much greater degree in young subjects and increased IL-6 production to a much greater degree in older subjects. Based on IL-10/IL-12 ratios, B. infantis resulted in the most anti-inflammatory profile of all of the probiotics. These results suggest that B. infantis CCUG 52486 has strong immunomodulatory potential compared with well-known commercial strains and that the immune response to probiotics may be influenced by ageing.
-
selective effects of Lactobacillus Casei Shirota on t cell activation natural killer cell activity and cytokine production
Clinical and Experimental Immunology, 2010Co-Authors: Honglin Dong, Ian Rowland, Linda V Thomas, Kieran Tuohy, Parveen YaqoobAbstract:Modulation of host immunity is an important potential mechanism by which probiotics confer health benefits. This study was designed to investigate the effects of a probiotic strain, Lactobacillus Casei Shirota (LcS), on immune function using human peripheral blood mononuclear cells (PBMC) in vitro. In addition, the role of monocytes in LcS-induced immunity was also explored. LcS promoted natural killer (NK) cell activity and preferentially induced expression of CD69 and CD25 on CD8(+) and CD56(+) subsets in the absence of any other stimulus. LcS also induced production of interleukin (IL)-1beta, IL-6, tumour necrosis factor (TNF)-alpha, IL-12 and IL-10 in the absence of lipopolysaccharide (LPS). In the presence of LPS, LcS enhanced IL-1beta production but inhibited LPS-induced IL-10 and IL-6 production, and had no further effect on TNF-alpha and IL-12 production. Monocyte depletion reduced significantly the impact of LcS on lymphocyte activation, cytokine production and natural killer (NK) cell activity. In conclusion, LcS activated cytotoxic lymphocytes preferentially in both the innate and specific immune systems, which suggests that LcS could potentiate the destruction of infected cells in the body. LcS also induced both proinflammatory and anti-inflammatory cytokine production in the absence of LPS, but in some cases inhibited LPS-induced cytokine production. Monocytes play an important role in LcS-induced immunological responses.
Michael Gleeson - One of the best experts on this subject based on the ideXlab platform.
-
Daily Probiotic’s (Lactobacillus Casei Shirota) Reduction of Infection Incidence in Athletes
2016Co-Authors: Michael Gleeson, Nicolette C. Bishop, Marta Oliveira, Pedro TaulerAbstract:(Lactobacillus Casei Shirota) reduction of infection incidence in athletes This item was submitted to Loughborough University's Institutional Repository by the/an author
-
effects of Lactobacillus Casei Shirota ingestion on common cold infection and herpes virus antibodies in endurance athletes a placebo controlled randomized trial
European Journal of Applied Physiology, 2016Co-Authors: Michael Gleeson, Nicolette C. Bishop, Lauren StruszczakAbstract:Aims To assess evidence of health and immune benefit by consumption of a Lactobacillus Casei Shirota probiotic in highly physically active people.
-
Effects of Lactobacillus Casei Shirota ingestion on common cold infection and herpes virus antibodies in endurance athletes: a placebo-controlled, randomized trial
2016Co-Authors: Michael Gleeson, Nicolette Bishop, Lauren StruszczakAbstract:Aims To assess evidence of health and immune benefit by consumption of a Lactobacillus Casei Shirota probiotic in highly physically active people. Methods Single-centre, population-based, randomized, double-blind, placebo-controlled trial. Daily ingestion of probiotic (PRO) or placebo (PLA) for 20 weeks for n = 243 (126 PRO, 117 PLA) university athletes and games players. Subjects completed validated questionnaires on upper respiratory tract infection symptoms (URS) on a daily basis and on physical activity status at weekly intervals during the intervention period. Blood samples were collected before and after 20 weeks of the intervention for determination of Epstein Barr virus (EBV) and cytomegalovirus (CMV) serostatus and antibody levels. Results URS episode incidence was unexpectedly low (mean 0.6 per individual) and was not significantly different on PRO compared with PLA. URS episode duration and severity were also not influenced by PRO. A significant time × group interaction effect was observed for plasma CMV antibody titres in CMV seropositive participants (p < 0.01) with antibody titre falling in the PRO group but remaining unchanged in the PLA group over time. A similar effect was found for plasma EBV antibody titres in EBV seropositive participants (p < 0.01) with antibody titre falling in the PRO group but increasing in the PLA group over time. Conclusions In summary, regular ingestion of PRO did not reduce URS episode incidence which might be attributable to the low URS incidence in this study. Regular ingestion of PRO reduced plasma CMV and EBV antibody titres, an effect that can be interpreted as a benefit to overall immune status
-
daily probiotic s Lactobacillus Casei Shirota reduction of infection incidence in athletes
International Journal of Sport Nutrition and Exercise Metabolism, 2011Co-Authors: Michael Gleeson, Nicolette C. Bishop, Marta Oliveira, Pedro TaulerAbstract:The purpose of this study was to examine the effects of a probiotic supplement during 4 mo of winter training in men and women engaged in endurance-based physical activities on incidence of upper respiratory-tract infections (URTIs) and immune markers. Eighty-four highly active individuals were randomized to probiotic (n = 42) or placebo (n = 42) groups and, under double-blind procedures, received probiotic (PRO: Lactobacillus Casei Shirota [LcS]) or placebo (PLA) daily for 16 wk. Resting blood and saliva samples were collected at baseline and after 8 and 16 wk. Weekly training and illness logs were kept. Fifty-eight subjects completed the study (n = 32 PRO, n = 26 PLA). The proportion of subjects on PLA who experienced 1 or more weeks with URTI symptoms was 36% higher than those on PRO (PLA 0.90, PRO 0.66; p = .021). The number of URTI episodes was significantly higher (p < .01) in the PLA group (2.1 ± 1.2) than in the PRO group (1.2 ± 1.0). Severity and duration of symptoms were not significantly different between treatments. Saliva IgA concentration was higher on PRO than PLA, significant treatment effect F(1, 54) = 5.1, p = .03; this difference was not evident at baseline but was significant after 8 and 16 wk of supplementation. Regular ingestion of LcS appears to be beneficial in reducing the frequency of URTI in an athletic cohort, which may be related to better maintenance of saliva IgA levels during a winter period of training and competition.
